InflaRx (IFRX) Accounts Payables (2016 - 2026)
InflaRx's (IFRX) quarterly Accounts Payables came in at $6.2 million in Q2 2026, down 100.0% year-over-year from $11020.4 billion in Q2 2025, and up 8.68% quarter-over-quarter from $5.7 million in Q1 2026.
Analysis
InflaRx (IFRX) Accounts Payables (2016 - 2026) Analysis & Trends
InflaRx has disclosed Accounts Payables across 11 years of filings, most recently posting $6.2 million for Q2 2026.
- In Q2 2026, Accounts Payables fell 100.0% year-over-year to $6.2 million; the TTM figure through Jun 2026 stood at $6.2 million (down 100.0% YoY), while the FY2025 annual figure was $6.1 million, down 100.0% from the prior year.
- Accounts Payables came in at $6.2 million for Q2 2026 at InflaRx, up from $5.7 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $12175.8 billion in Q4 2024 to a low of $5.0 million in Q1 2023.
- Average Accounts Payables over 5 years is $1288.7 billion, with a median of $8.4 million recorded in 2022.
- The largest YoY upside for Accounts Payables was 119761813.95% in 2025 against a maximum downside of 100.0% in 2025.
- Over 5 years, Accounts Payables stood at $5.1 million in 2022, then surged by 153.19% to $12.9 million in 2023, then jumped by 94505590.22% to $12175.8 billion in 2024, then plunged by 100.0% to $6.3 million in 2025, then decreased by 1.91% to $6.2 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $6.2 million in Q2 2026, $5.7 million in Q1 2026, and $6.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 25.08 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 6.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.17 Mn |
| Mar 31, 2026 | 5.67 Mn |
| Dec 31, 2025 | 6.29 Mn |
| Sep 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 11,020.37 Bn |
| Mar 31, 2025 | 8.80 Mn |
| Dec 31, 2024 | 12,175.82 Bn |
| Sep 30, 2024 | 12.87 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 8.26 Mn |
| Dec 31, 2023 | 12.88 Mn |
| Sep 30, 2023 | 6.53 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Mar 31, 2023 | 4.95 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 7.50 Mn |
| Jun 30, 2022 | 8.44 Mn |
| Mar 31, 2022 | 10.67 Mn |
| Dec 31, 2021 | 9.81 Mn |
| Sep 30, 2021 | 13.58 Mn |